Post by Alira Health

Regulators and HTA bodies increasingly call for endpoints in neurological disorder treatment trials that are both clinically meaningful and patient-relevant. Early and structured engagement with clinicians, payers, patients, and caregivers, throughout the clinical development of neurological treatments, is critical to ensuring that endpoints capture outcomes that matter most in real life, both from clinical and patient standpoints. Read this article to: 🔹review valuable stakeholder groups and perspectives they can provide to companies preparing for clinical trials in neurological disorders. 🔹identify key risks posed by a lack of engagement with these stakeholders.  🔹access best practices for coordinated multi-stakeholder engagement throughout product development that lead to positive trial outcomes and successful reimbursement and adoption.  Start reading: https://lnkd.in/edxWMpKy